peramivir (Rapivab)

From Aaushi
Jump to navigation Jump to search

Introduction

FDA-approved Dec 2014

Indications

  • uncomplicated influenza in adults with symptoms of <= 2 days' duration

Dosage

Adverse effects

Mechanism of action

Notes

More general terms

References

  1. FDA MedWatch http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm187814.htm
  2. 2.0 2.1 Kohno S et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 2010 Nov; 54:4568 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20713668
  3. FDA News Release. December 22, 2014 FDA approves Rapivab to treat flu infection http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427755.htm
  4. Peramivir prescribing information http://rapivab.com/wp-content/uploads/2014/12/Rapivab-PI.pdf

Database